C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Historical Holders from Q4 2020 to Q3 2025

Symbol
CCCC on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
71,366,920
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
52,538,995
Holdings value
$116,636,299
% of all portfolios
0%
Number of holders
96
Number of buys
47
Number of sells
-63
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $50,277,776 22,647,647 Point72 Asset Management, L.P. 17 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $20,959,588 +$20,959,588 9,441,256 RA Capital Management, L.P. 17 Oct 2025
Bain Capital Life Sciences Fund II, L.P. 6.25% $13,453,200 6,060,000 BCLS II Equity Opportunities, LP 17 Oct 2025
WASATCH ADVISORS LP 6.8% -33.6% $10,773,085 -$5,817,712 4,852,741 -35.1% Wasatch Advisors LP 30 Sep 2025
MORGAN STANLEY 6.7% +26% $7,030,567 +$1,363,928 4,750,383 +24.1% Morgan Stanley 30 Jun 2025
ORBIMED ADVISORS LLC 5% -22.9% $7,921,728 -$2,413,704 3,568,346 -23.4% OrbiMed Capital LLC 30 Sep 2025
BlackRock, Inc. 2.5% $2,513,362 1,756,613 BlackRock, Inc. 30 Jun 2025

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 52,538,995 $116,636,299 -$3,488,602 $2.22 96
2025 Q2 54,715,914 $78,242,864 -$14,672,718 $1.43 102
2025 Q1 64,100,740 $102,562,013 -$12,577,745 $1.6 113
2024 Q4 64,400,415 $231,841,449 -$9,805,080 $3.6 113
2024 Q3 64,180,724 $365,858,667 +$21,073,945 $5.7 118
2024 Q2 60,887,928 $281,302,982 +$5,545,189 $4.62 114
2024 Q1 58,201,499 $475,505,218 +$93,890,692 $8.17 104
2023 Q4 47,001,017 $265,585,658 +$85,422,229 $5.65 91
2023 Q3 34,671,251 $64,488,483 -$134,435 $1.86 82
2023 Q2 34,220,399 $94,120,957 -$9,383,233 $2.75 96
2023 Q1 37,418,446 $117,492,869 -$15,156,032 $3.14 117
2022 Q4 39,224,213 $231,404,815 -$9,766,681 $5.9 113
2022 Q3 39,456,577 $346,000,579 -$2,524,371 $8.77 115
2022 Q2 39,425,650 $297,247,580 -$39,977,861 $7.54 111
2022 Q1 37,306,180 $904,604,832 +$6,530,479 $24.26 120
2021 Q4 35,893,940 $1,154,835,979 +$16,687,200 $32.2 115
2021 Q3 34,491,766 $1,542,710,693 +$110,759,163 $44.68 110
2021 Q2 31,945,852 $1,209,520,921 +$259,679,873 $37.84 106
2021 Q1 25,097,387 $926,788,055 +$90,401,887 $36.99 83
2020 Q4 22,706,689 $743,535,975 +$718,564,975 $33.13 75